Drugs in MeSH Category Sequestering Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	COLESTIPOL HYDROCHLORIDE	colestipol hydrochloride	TABLET;ORAL	220012-001	Sep 15, 2025	AB	RX	No	No
Edenbridge Pharms	COLESTIPOL HYDROCHLORIDE	colestipol hydrochloride	TABLET;ORAL	217667-001	Aug 16, 2024	AB	RX	No	No
Pfizer	COLESTID	colestipol hydrochloride	TABLET;ORAL	020222-001	Jul 19, 1994	AB	RX	Yes	No
Riconpharma Llc	COLESTIPOL HYDROCHLORIDE	colestipol hydrochloride	TABLET;ORAL	217462-001	Dec 3, 2024	AB	RX	No	No
Pfizer	COLESTID	colestipol hydrochloride	GRANULE;ORAL	017563-004	Sep 22, 1995	AB	RX	Yes	Yes

Market dynamics and patent landscape for sequestering agents (NLM MeSH): exclusivity, Orange Book, and generic/biosimilar risk

Last updated: June 17, 2026

Sequestering agents sit at the intersection of chelation therapy and supportive oncology/critical care. Market dynamics are driven by (1) narrow indications and acuity-based demand, (2) limited branded competition due to complex formulation and sterile/manufacturing constraints, and (3) patent estates that often split across active substance preparation, chelation chemistry, specific salt/hydrate forms, dosing regimens, and method-of-use. For North America, the most important hard-IP screens are Orange Book small-molecule listings (where applicable) and FDA exclusivity triggers, with generic entry risk most concentrated near the expiration of formulation and method-of-use patents plus any unexpired exclusivity.

This document provides a business-oriented mapping of how to analyze the patent estate and competitive timing for sequestering agents by category, and where generics typically face the strongest IP barriers.

---

Which drugs qualify as “sequestering agents” in NLM MeSH, and what are their commercial profiles?

NLM MeSH “Sequestering Agents” typically covers chelating or binding agents used to reduce bioavailability/toxicity of metals or to support disease management where metal binding is therapeutic. Common commercial and regulatory targets across this class include:

• Iron chelation (transfusion-related iron overload)
• Lead/metal decontamination (toxic exposures)
• Binding of divalent metal ions in specific therapeutic settings
• Chelation used as supportive therapy in oncology or critical care workflows

Business implication: demand is often tied to patient population size (chronic disorders) or case volume (toxicity events), and procurement is skewed toward hospital formularies and continuity-of-therapy for chronic chelation.

What are the main subcategories that matter for patent strategy?

1. Iron chelators
   Key patent issues: salt form/hydrate, synthesis route, polymorphs, and oral dosing schedules.
2. Lead or heavy-metal chelators
   Key patent issues: chelation kinetics, dosing regimens, and sterile preparation where parenteral forms exist.
3. Other metal-binding sequestering agents
   Key patent issues: method-of-use (indication-specific), formulation stability, and administration format.

---

Which patents protect sequestering agents, and how are the estates structured?

Sequestering agent patent estates usually cluster into four buckets:

1. Composition of matter (active or its salt/hydrate/polymorph)
2. Formulation patents (particle size, excipient systems, solubilizers, stability, coating, and dosage unit specs)
3. Method-of-use patents (dose regimens, patient subsets, disease-stage criteria, and monitoring-based instructions)
4. Manufacturing-process patents (scale-up synthesis, purification steps, crystallization conditions, and impurity control)

What does the typical Orange Book coverage look like?

For small-molecule chelators, the Orange Book often lists:

• Multiple patents tied to the same NDA for different aspects (composition vs formulation vs method-of-use).
• Patent expiration that is not synchronized, producing multi-step “windows” where generics can file but not launch without carve-outs or design-arounds.

How many patents commonly cover one sequestering agent?

In practice, branded sequestering agents with mature FDA histories often show:

• A core composition patent family
• 2 to 6 formulation and/or salt form patents
• Several method-of-use claims

Business implication: even after the composition patent falls, later-expiring formulation or regimen patents can block generic launch unless the generic product can qualify under a different patent landscape or they win Paragraph IV litigation/settlement.

---

When does exclusivity expire for sequestering agents, and how do exclusivity and patents interact?

Exclusivity is not uniform across the class. The practical pattern is:

• Composition patents drive the outer boundary for generic competition.
• Regulatory exclusivity (5-year new chemical entity, 3-year new clinical investigation, 7-year orphan for qualifying drugs, and 12-year biologics not usually relevant for chelators) can extend entry timing even when some patents have expired.
• Orange Book unexpired patents are the gating items for ANDA “paragraph IV” triggers.

Exclusivity timeline mechanics (what matters in filings)

• ANDA applicants typically use Paragraph IV certifications to challenge specific listed patents.
• Market entry is blocked until:
  • all patents tied to the NDA expire or are successfully cleared, and
  • any blocking exclusivity periods end.

What is the most common lockup failure mode for generics?

Generic strategists often assume composition patent expiration yields immediate launch. In sequestering agents, formulation and method-of-use patents can remain active enough to keep the NDA blocked and force:

• a later launch, or
• an authorized generic strategy, or
• a settlement-based “carve-out” entry date.

---

What generic entry risks exist for sequestering agents after Paragraph IV challenges?

Paragraph IV risk is driven by:

• claim breadth in composition/formulation patents,
• whether the generic’s physicochemical profile (salt form, hydrate, polymorph) matches the branded product, and
• overlap between method-of-use claims and the generic’s approved dosing.

How do design-around attempts usually fail?

Common failure points:

• Selecting a “different” salt or hydrate that still falls within claim scope via doctrine equivalents.
• Manufacturing impure products or using a crystallization method that does not avoid a “process claims” path.
• Selecting dosing regimens that still map to method-of-use claim language.

What settlement terms typically appear in sequestering agent disputes?

Where disputes settle without a full win, the market outcome is usually a:

• delayed launch date tied to the last expiring challenged patent, or
• licensed entry with royalty (often rare in older chelators unless there is a clear optimization requirement), or
• a carve-out specific to strength or dosage form.

---

What formulation patents most often block generic launch of sequestering agents?

Formulation is where generic products often get trapped in sequestering agents due to:

• stability constraints for chelating agents (water content, degradation pathways, and oxidative sensitivity),
• solubility and bioavailability tuning,
• crystalline form control (polymorph/hydrate selection), and
• excipient selections that impact absorption.

Which formulation attributes are targeted by claims?

• salt form and hydrate selection
• crystal morphology and particle size distribution
• stabilizer/excipient system for moisture and temperature stability
• capsule/tablet fill specs and manufacturing controls
• sterile formulation and reconstitution instructions (for parenteral chelators)

Business implication: a generic can have the “right” active ingredient but still face infringement risk if it uses a claimed crystalline form or stability-preserving formulation.

---

Which method-of-use patents matter most for sequestering agents?

Method-of-use protection is commonly tied to:

• starting dose and escalation protocols,
• dosing interval and maximum daily dose,
• indication-specific criteria (iron overload thresholds; toxicity severity scoring; monitoring frequency),
• patient subpopulations (age, renal function, disease stage), and
• co-medication rules.

What is the litigation pattern for method-of-use claims?

Method claims are often easier to compare on-label than formulation patents, so infringement arguments frequently focus on:

• whether the generic’s FDA-approved labeling triggers the same dosing instructions,
• whether the method claim requires specific patient markers, and
• whether generic labeling is “carved” to avoid claim elements.

Business implication: FDA label design becomes an IP variable. Even when the active substance is generic-ready, the approved directions can keep the product in the claim zone.

---

Which companies dominate the sequestering agent market, and where is revenue concentrated?

Commercial power in this class tends to sit with manufacturers that can:

• maintain reliable supply of hard-to-stabilize products,
• support hospital distribution and distribution agreements,
• carry chronic-therapy logistics for iron chelation, and
• offer strong patient support programs.

Business implication: in sequestering agents, procurement relationships and supply continuity often decide market share as much as patent timing does.

---

What is the Orange Book status of sequestering agents, and how should it be screened?

A correct Orange Book screening workflow for sequestering agents should:

1. pull all listed patents for each NDA/ANDA target,
2. map patents to categories (composition, formulation, method-of-use, process),
3. record expiration dates and exclusivity barriers, and
4. classify each listed patent by litigation/Paragraph IV posture (if known).

Orange Book risk metric for generic planning

A useful internal metric is the “last viable patent” date:

• the latest expiration among patents that are plausibly hard to design around, excluding patents already found invalid/unenforceable in final judgments.

Business implication: the generic launch “clock” is not the earliest patent loss; it is the last un-cleared blocking patent.

---

What patent litigation affects sequestering agents, and what case outcomes drive market entry?

Sequestering agent litigation typically turns on:

• claim construction for salt/hydrate/crystal form patents,
• proof of infringement via analytical testing for form and composition,
• process proof for manufacturing patents (harder when the generic uses different supply routes), and
• label-based infringement for method-of-use patents.

How do litigation outcomes translate into launch calendars?

• A final validity win on the key patents can unlock earlier launch even if multiple patents remain listed.
• A settlement often sets a fixed “designated entry date,” aligned to the last blocking patent or a negotiated date.

Business implication: settlement calendars can be more operationally decisive than courtroom merits for investment timing.

---

How do iron chelators compare with other sequestering agents in patent density and launch barriers?

Across the class, iron chelators generally show:

• longer brand duration and mature patent estates,
• multiple formulation and regimen patents, and
• heavy dependence on chronic dosing adherence.

Other metal decontamination agents often show:

• fewer but more regimen- and administration-driven claims,
• market exposure tied to acute use and procurement cycles.

Patent density comparison (practical expectation)

• Iron chelators: highest density (composition + multiple form + method-of-use)
• Decontamination chelators: moderate density (method-of-use + administration/formulation, depending on route)

Business implication: the highest generic entry friction is usually in chronic iron chelation due to labeling, stability/formulation complexity, and multiple late-expiring patents.

---

Where are biosimilar risks relevant for sequestering agents?

Biosimilar pathways apply only if the active therapeutic is biologic. Sequestering agents in MeSH are overwhelmingly small molecules or classic chelators, so biosimilar risk is generally not a primary planning dimension.

Business implication: focus on ANDA, not BLA-to-biosimilar competition, unless a specific sequestering agent in the scope is biologic.

---

What manufacturing/IP barriers most often block sequestering agent generics?

Manufacturing is an IP gate through:

• controlled crystallization and impurity specifications,
• stability-driven packaging formats,
• validated dissolution profiles and bioequivalence requirements, and
• tight process windows needed to achieve identical chelation-relevant physicochemical properties.

Specific barriers that repeatedly show up

• replication of the branded salt/hydrate or polymorph
• achieving dissolution and bioavailability consistent with the reference product
• proving comparability of impurities and residual solvents
• meeting sterile compounding rules for parenterals (where present)

---

Key takeaways

• Sequestering agents typically have patent estates that split into composition, formulation (salt/hydrate/polymorph), and method-of-use regimen claims. The last blocking patent and any unexpired regulatory exclusivity often control generic timing more than the first composition expiration.
• Generic entry risk is concentrated in formulation and labeling-driven method-of-use patents, where design-around is difficult and infringement can hinge on physicochemical matching or on-label dosing instructions.
• For market and licensing decisions, Orange Book-driven mapping to a “last viable patent” date, plus an assessment of whether the proposed generic can avoid the branded salt/formulation and labeling elements, is the highest-signal workflow.
• Biosimilar risk is typically not central for sequestering agents if the target products are small-molecule chelators; competitive planning should focus on ANDA and Paragraph IV posture.

---

FAQs

1) How should I prioritize which sequestering agent patents to challenge in a Paragraph IV ANDA?
Prioritize patents that cover the active substance salt/hydrate or the approved dosing regimen with the broadest claim elements, then formulation patents tied to stability and crystalline form, because these drive both infringement proof and design-around feasibility.

2) What evidence most often determines infringement for chelator formulation patents?
Analytical comparison of the generic product against the branded reference for salt/hydrate/polymorph and related physicochemical characteristics, plus stability and dissolution profile evidence where claims tie to those attributes.

3) Do sequestering agent method-of-use patents block generics even when the active ingredient is generic?
Yes, when the generic’s label includes dosing instructions that satisfy the method claim elements. Label carving can be a decisive variable.

4) What market timing inputs matter most for investors evaluating generic sequestering agent entry?
The last un-cleared Orange Book blocking patent expiration, the presence of regulatory exclusivity, and any known settlement entry dates tied to litigation outcomes.

5) Are there typical geographic differences in sequestering agent patent enforceability?
Yes. U.S. launch timing is driven by Orange Book and ANDA litigation/settlement calendars; in parallel, European and other jurisdictions can impose different claim scopes and enforcement timelines, shaping overall licensing leverage.

---

References

1. U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. NLM. Medical Subject Headings (MeSH): Sequestering Agents. National Library of Medicine.
3. U.S. FDA. ANDA Paragraph IV Certification and Patent Dispute Resolution (Hatch-Waxman framework). FDA.